Osimertinib as Salvage Therapy in Advanced Non‐Small Cell Lung Cancer After Aumolertinib Resistance With T790M Mutation: A Case Report

ABSTRACT The third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is recommended universally as the standard treatment for non‐small cell lung cancer (NSCLC) carrying the EGFR T790M mutation. With the approval of multiple third‐generation EGFR‐TKIs, questions...

Full description

Bibliographic Details

Published in:	Clinical Case Reports
Main Authors:	Yongtong Tang, Jilan Xu, Qingle Chen, Jianping Lu, Li Ren, Taihe Lan, Taihua Liao, Xiaoling Chen, Hui Yi, Jun Zhang, Jie Huang
Format:	Article
Language:	English
Published:	Wiley 2025-02-01
Subjects:	aumolertinib epithelial growth factor receptor osimertinib resistance
Online Access:	https://doi.org/10.1002/ccr3.70219